Abstract
A large proportion of transgender women in Hyderabad, India (150/223, 67.3%) expressed interest in a wide range of topical, oral, and intravenous medications for skin lightening; however, despite government regulations and the potential health risks, persistent demand for skin lightening underscores the need for better patient education and safer skin care practices for this marginalized community.
JMIR Dermatol 2025;8:e66822doi:10.2196/66822
Keywords
Introduction
The Government of India’s recent amendments to the Drugs and Magic Remedies Act proposed increased penalties for marketing and advertising skin fairness creams [
]. Yet, conventional Indian beauty standards still drive demand for skin-lightening products (SLPs) among women in India and transfeminine communities. Literature on skin-lightening practices among transgender people is limited. Transgender women undergoing estrogen therapy have an increased risk of melasma, which may be treated with skin-lightening agents like hydroquinone [ ]. An ethnographic study of Indonesia’s transfeminine waria community found that members sought SLPs to feel more feminine and attract male attention [ ]. Similar motivations were documented among Thailand’s transgender entertainers [ ].The Health Needs and Aesthetic Preferences Assessment of the Hyderabad Trans Community is a large study evaluating the social and health history of transgender and hijra women in India (N=300). As part of that study, we evaluated the prevalence of interest in skin-lightening treatments, the products used, and the financial costs involved.
Methods
Study Design
This cross-sectional survey study was conducted at Mitr Clinic (Hyderabad, India), using consecutive sampling. The survey was developed by the research team and administered in Hindi, Telugu, or English. The inclusion criteria were as follows: hijra and/or transgender women aged ≥18 years, seeking female gender affirmation, and South Asian ancestry. Transgender men, individuals seeking male gender affirmation, and individuals aged <18 years were excluded. Dollar amounts were estimated based on the March 19, 2023, exchange rate.
Ethical Considerations
Because some community members have limited literacy, verbal consent was obtained before data collection. No protected health information was collected. Institutional review board (IRB) approvals were obtained from the University of Pennsylvania and YR Gaitonde Centre for AIDS Research and Education—the clinic’s overseeing nonprofit. Remuneration (₹500 [US $5.84]) was provided to patients for their time and participation.
Results
An IRB addendum approved in December 2023 enabled 74.3% (223/300) of participants to respond to skin lightening–related questions. More than two-thirds (150/223, 67.3%) of respondents expressed interest in skin lightening, of whom 43.3% (65/150) used SLPs. The overall prevalence of SLPs among respondents was 29.1% (65/223). Further, 1.3% (2/150) of respondents used SLPs previously but lost interest, and 3.1% (7/223) could not recollect or identify the products they used. Money spent on skin lightening varied from ₹25 (US $0.30) to ₹70,000 (US $843; median ₹570 [US $7], IQR ₹2225 [US $27]). Patients sometimes used multiple products (
).Type of product used | Active ingredients in products |
Topical treatments (n=23) |
|
Oral medications (n=2) |
|
Intravenous medications (n=16) |
|
Alternative (herbal/Ayurvedic/Unani; n=5) |
|
Marketed beauty creams (n=15) |
|
aThe n values in this column refer to the number of products reported.
bThe n values in this column refer to the number of products that contained the active ingredients listed in this column.
Discussion
Our study highlights the considerable interest in SLPs but marginally low prevalence of SLP use (likely due to financial barriers) among hijra and transgender women. Survey studies on cisgender populations in India indicate that SLPs have widespread prevalence (range 34%-60%) [
, ]. Deeply rooted cultural norms associate lighter skin with economic prosperity and beauty, leading to widespread use even among South Asian immigrant communities [ ]. Although 67.3% of our respondents expressed interest in skin lightening, only 29.1% used SLPs—a lower rate than in cisgender communities. Within the colorism context, transfeminine individuals may view skin lightening as an accessible method for facilitating gender affirmation and social acceptance, as observed in other Asian countries.Transgender women often face stigma and discrimination in health care settings, preventing them from seeking care [
]. Additionally, many transgender women in India engage in sex work, which acts a strong economic driver for investing in physical appearance (eg, undergoing skin treatments to achieve a desired aesthetic) [ ]. Although many respondents were interested in skin lightening, less than half used SLPs, which included herbal mixtures from local shops and intravenous glutathione injections.A study on SLPs used in India reported topical medication misuse prior to seeing a dermatologist [
]. The combination of hydroquinone, mometasone, and tretinoin cream is a common, over-the-counter melasma treatment in India [ ]. Glutathione injections, though popular and expensive, have questionable efficacy [ ]. Some alternative, traditional remedy–based medications are often cheaper. Popular marketed beauty creams use ingredients like kojic acid, niacinamide, and arbutin, which have been studied for their effects on skin pigmentation and complexion [ ]. Chronic steroid use, while lightening some patients’ skin, may result in skin atrophy and other side effects [ ]. Antifungal creams may treat pigmentary changes resulting from infections like pityriasis versicolor but have no additional lightening effects. Only 1 respondent reported using sunscreen daily, beyond sun protection factors in beauty creams.Almost half of our respondents use medications with skin-lightening properties—mostly purchased over the counter. After the COVID-19 pandemic, the average hijra community member’s earnings decreased from US $7 to US $13 per day to less than US $2 per day [
]. Many members are of low socioeconomic status and have been reported to seek hormonal and surgical care from unqualified medical practitioners because allopathic treatments are costly [ ]. Despite the Indian government’s regulatory efforts, interest in SLPs persists among transgender women [ ]. However, only a fraction can afford to regularly use skin-lightening treatments. Given the potential health and financial risks, patient education about safe skin care is crucial for transgender women to make informed health decisions.This study had several limitations, which we hope to address in follow-up studies. Participants’ informal occupations (eg, begging and sex work) precluded an accurate income assessment. Furthermore, the ad hoc survey lacked prior psychometric validation; this may have affected the accuracy of estimates regarding SLP use. Lastly, data on individual product costs and usage durations were not collected, limiting insights into the costs of long-term use.
Acknowledgments
We thank the Fulbright Program and the United States-India Educational Foundation (USIEF) for financially supporting this project.
Conflicts of Interest
None declared.
References
- Raj S, Sampat B, Kajla T, Singh H. Dark side of skin‐lightening products: social responsibility of advertisers. Int Soc Sci J. Sep 2022;72(245):525-541. [CrossRef]
- Yeung H, Kahn B, Ly BC, Tangpricha V. Dermatologic conditions in transgender populations. Endocrinol Metab Clin North Am. Jun 2019;48(2):429-440. [CrossRef] [Medline]
- Idrus NI, Hymans TD. Balancing benefits and harm: chemical use and bodily transformation among Indonesia’s transgender waria. Int J Drug Policy. Jul 2014;25(4):789-797. [CrossRef] [Medline]
- Farber R. Transitioning Thailand: techno‐professionalism and nation‐building in the transgender entertainment industry. Gend Work Organ. Nov 2024;31(6):2489-2510. [CrossRef]
- Jacob SM, Thillaikarasi A. Awareness on skin lightening practice and their side effects among nursing staff in a tertiary care centre. Indian J Dermatol. 2023;68(3):356. [CrossRef] [Medline]
- Wong C, Wong S, Tang H, Minocha R, Singh R, Grills N. Use of skin-lightening products among outpatient attendees in a North Indian hospital. Indian J Public Health. 2017;61(2):137-140. [CrossRef] [Medline]
- Banala M, Mamidipaka A, Ogunleye T. Skin-lightening product use among South Asian Americans: cross-sectional survey study. JMIR Dermatol. Nov 2, 2023;6:e49068. [CrossRef] [Medline]
- Nuttbrock L, editor. Transgender Sex Work and Society. Harrington Park Press; 2019. ISBN: 9781939594402
- Godse KV, Zawar V. Mometasone menace in melasma. Indian J Dermatol. Jul 2012;57(4):324-326. [CrossRef] [Medline]
- Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. Jan 31, 2018;8(1):15-21. [CrossRef] [Medline]
- Wang YH, Avonto C, Avula B, Wang M, Rua D, Khan IA. Quantitative determination of α-arbutin, β-arbutin, kojic acid, nicotinamide, hydroquinone, resorcinol, 4-methoxyphenol, 4-ethoxyphenol, and ascorbic acid from skin whitening products by HPLC-UV. J AOAC Int. 2015;98(1):5-12. [CrossRef] [Medline]
- Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol. Sep 2014;59(5):456-459. [CrossRef] [Medline]
- Chakrapani V, Newman PA, Sebastian A, Rawat S, Shunmugam M, Sellamuthu P. The impact of COVID-19 on economic well-being and health outcomes among transgender women in India. Transgend Health. Oct 1, 2022;7(5):381-384. [CrossRef] [Medline]
- Singh Y, Aher A, Shaikh S, Mehta S, Robertson J, Chakrapani V. Gender transition services for hijras and other male-to-female transgender people in India: availability and barriers to access and use. Int J Transgend. Jan 2, 2014;15(1):1-15. [CrossRef]
Abbreviations
IRB: institutional review board |
SLP: skin-lightening product |
Edited by Eva Parker; submitted 24.09.24; peer-reviewed by Howa Yeung, Jules Lipoff; final revised version received 03.03.25; accepted 19.04.25; published 29.05.25.
Copyright© Sriram Palepu, Vasudeva Murthy Sindgi, Aylur Kailasom Srikrishnan, Carrie Kovarik. Originally published in JMIR Dermatology (http://derma.jmir.org), 29.5.2025.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Dermatology, is properly cited. The complete bibliographic information, a link to the original publication on http://derma.jmir.org, as well as this copyright and license information must be included.